Page 1,313«..1020..1,3121,3131,3141,315..1,3201,330..»

Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities – Health News Office

Posted: October 28, 2019 at 12:42 pm

The Global Medical Waste Managementmarket research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, Medical Waste Management market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, Medical Waste Management market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request?report_id=Medical-Waste-Management-Market-BWC7

Medical Waste Management Market: Competitive Analysis by Key Players:

Medical waste management is one of the biggest challenges being faced by the healthcare organizations currently. It is often complicated by state and local regulation. The major market players in the medical waste management are focusing on explaining their portfolio of services and products in the waste management market. Such as BioMedical Waste Solutions, LLC, Suez Environment, Stericycle, Republic Services, Daniels Sharpsmart Inc., Remondis Ag & Co. Kg, Veolia Environnement S.A., XMED Disposal, Inc., American Ecology Corporation, Suez Environnement S.A, and other prominent players.

The Global Medical Waste Management Market also explains the competitive landscape among the major key players of the market, based on various parameters, such as:

Awareness among people regarding the disposal of medical waste, and taking care of their safety from harmful medical waste are the major trend currently driving the market growth. Regulated waste disposal generally costs more than unregulated waste disposal. Growth of the overall medical and healthcare industry is driving the demand for medical waste management systems. In the U.S. and European countries, due to strict regulations, most medical waste management service providers require government permits, approvals, certificates from all jurisdictions in which they operate. In India, the Ministry of Environment and Forests (MoEF), Government of India, declare the Medical waste management and Handling Rules, 1998 and the Bio-Medical Waste (Management and Handling) (Amendment) Rules, 2003, to provide legal and mandatory guidelines for healthcare and medical waste management industry

Medical Waste Management Market Insights

The new study study of Medical Waste Management Market anticipated to reach US$ XXX Million with a significant CAGR of 5.3% in the forecast period of 2015-2025. The growing population across the globe is expanding the number of patients, resulting in the rising volume of medicinal waste. Also, the increasing prevalence of diseases such as cancer & other chronic disorders and increasing geriatric population result in higher demand for these propelled the medical waste management market. The Central Pollution Control Board has additionally issued guidelines on the Central Bio-medical Waste Treatment Facilities (CBWTF). The expanding number of innovative initiatives by the government authorities is driving the medical waste management market. The developing trend of government R&D in technological research are the prime aspects that are straightforwardly responsible for driving the global medical waste management market. The Asia Pacific is anticipated to open growth prospects for the medical waste management market in the forecast period of 2019-25 in the healthcare sector.

Get a Sample Report for more Expert and Official insights: @ https://www.reportocean.com/industry-verticals/sample-request?report_id=Medical-Waste-Management-Market-BWC7

Regional Analysis:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global Medical Waste Management Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global Medical Waste Management Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Medical Waste ManagementMarket.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe Medical Waste Management Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers side and industries, to obtain and verify the data related to the study of the Global Medical Waste ManagementMarket. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the GlobalMEDICAL WASTE MANAGEMENT Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Get in Touch with Us:

Name: David McKee

Email: [emailprotected]

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

Here is the original post:
Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities – Health News Office

FDA Approves Medicines360’s LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest…

Posted: October 28, 2019 at 12:42 pm

"Our mission has always been to meet the diverse and unique health needs of all women, and this approval of LILETTA for up to six years means women have even greater flexibility and choice when it comes to their reproductive health," said Jessica Grossman, M.D., CEO of Medicines360. "Studying our products in robust clinical trials, like ACCESS IUS, ensures we can provide quality birth control that works for a broad range of women in the U.S., something we take pride in for leading the way."

The FDA approval was based on a review of additional efficacy and safety data from the largest ongoing Phase 3 clinical trial of an intrauterine system in the U.S., ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS), with 1,751 U.S. women receiving LILETTA. LILETTA proved to be more than 99 percent effective in preventing pregnancy for up to 6 years in a diverse population of women. The study population in the ACCESS IUS trial included women of various ages, races, and body mass index (BMI).

"I hear all the time from women that they want a reliable and long-term option for birth control that is reversible," said Carolyn Westhoff, M.D., MSC, chief of the Division of Family Planning, Sarah Billinghurst Solomon Professor of Reproductive Health, Department of Obstetrics and Gynecology, Professor of Population and Family Health and Epidemiology, Columbia University, and investigator in the ACCESS IUS study. "This groundbreaking trial has given healthcare providers the ability to confidently offer women the option of pregnancy prevention for up to six years."

LILETTA is a hormone-releasing system placed in a woman's uterus to prevent pregnancy for up to six years. The system should be replaced after six years if continued use is desired. Medicines360 received initial approval of LILETTA in February 2015. Since then, Medicines360 and Allergan have continued to invest in the product, which has led to the introduction of the single-handed inserter and, now, the extended duration of use for up to six years.

LILETTA is commercially available in the U.S., and through Medicines360's unique mission-driven model, LILETTA is available at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.

"Our partnership with Medicines360 helps to ensure that women can obtain an effective, long-term birth control option," said David Nicholson, Ph.D., Allergan's Executive Vice President and Chief Research and Development Officer. "Our goal is to provide a variety of contraceptive options for women so they and their healthcare providers can choose what is best for them. We are proud to deliver a product that now provides women with an even longer duration of pregnancy prevention."

ABOUT LILETTA

Indication

LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 6 years.

Important Risk Information About LILETTA

LILETTA does not protect against HIV or STDs.

Available by prescription only.

Please see full Prescribing Information for LILETTA.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women's health pharmaceutical company with a mission to remove cost as a barrier to health by developing and providing affordable Women's Health products. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit http://www.medicines360.org

About Allergan Women's Healthcare

Allergan is a leader in women's healthcare that is dedicated to developing and commercializing best-in-class pharmaceuticals to improve the health and wellness of women. Allergan takes a holistic and a best-in-class approach to women's healthcare as it prioritizes educational partnerships with OB/GYNs. The mission of Allergan Women's HealthCare extends beyond its pharmaceutical products to ensure that all women can make informed decisions about their health and have access to high-quality medications. Allergan is committed to investing in programs that support the education and well-being of all women.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website atwww.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Medicines360

Home

View original post here:
FDA Approves Medicines360's LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest...

Posted in Regenerative Medicine | Comments Off on FDA Approves Medicines360’s LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest…

The Bounce is On in Predictive Technology Group Inc (OTCMKTS:PRED) – The Oracle Dispatch

Posted: October 28, 2019 at 12:42 pm

As we head into the fresh weekof trading, note the action on Friday in shares of Predictive Technology Group Inc (OTCMKTS:PRED). The rally looks tobe related to news of an uplist onto the OTCQX tier of the OTC market. But wewould also point out the companys announcement that a team mostly from PRED(including Kenneth Ward, M.D., laboratory director of Predictive Laboratoriesand chief executive officer of Juneau Biosciences; Rakesh Chettier M.S.,director of biostatistics of Predictive Laboratories; and Hans Albertsen,Ph.D., chief scientific officer of Juneau Biosciences) has received the 2019Endometriosis Special Interest Group (EndoSIG) Prize Paper in the Best inClinical/Population Science category.

According to the release, Dr. Albertsens presentation entitled Cytoskeletal and extracellular matrix genes are key contributors in the pathogenesis of endometriosis was delivered at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo in Philadelphia on October 16. EndoSIG is a member group of ASRM aimed at fostering increased interest in the biology, pathophysiology and clinical management of endometriosis.

Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).

The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.

The company was formerly knownas Global Enterprises Group, Inc. and changed its name to Predictive TechnologyGroup, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005and is headquartered in Salt Lake City, Utah.

According to companymaterials, Predictive Technology Group aims to revolutionize patient carethrough predictive data analytics, novel gene-based diagnostics and companiontherapeutics through its subsidiaries Predictive Therapeutics, PredictiveBiotech, and Predictive Laboratories. These subsidiaries are focused onendometriosis, scoliosis, degenerative disc disease and human cell and tissueproducts. The subsidiaries use genetic and other information as cornerstones inthe development of new diagnostics that assess a persons risk of illness andtherapeutic products designed to identify, prevent and treat diseases moreeffectively.

Find out when $PRED reaches critical levels. Subscribe toOracleDispatch.com Right Now by entering your Email in the box below.

As noted above, PRED just announced that a team mostly from the company has received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the Best in Clinical/Population Science category.

Weve witnessed 28% tacked on to share pricing for the name in the past week. In addition, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed topping 120% over what the stock has registered over the longer term.

We are honored to receive this prestigious award from the ASRM Research Committee, said Dr. Albertsen. As endometriosis is generally characterized as a hormonal and inflammatory disease, current therapies often come with significant debilitating side effects. The scientific breakthroughs reported in these award-winning discoveries provide Predictive with insights into new non-hormonal therapies.

At this time, carrying acapital value in the market of $475M, PREDhas a bankroll ($1.8M) of cash on the books, which is balanced by about $14.1Min total current liabilities. One should also note that debt has been growingover recent quarters. PRED is pulling in trailing 12-month revenues of $43.5M.In addition, the company is seeing major top-line growth, with y/y quarterlyrevenues growing at 88%. You can bet we will update this one again as newinformation comes into view. Sign-up forcontinuing coverage on shares of $PRED stock, as well as other hot stock picks,get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $PRED, either long orshort, and we have not been compensated for this article.

Post Views: 223

Original post:
The Bounce is On in Predictive Technology Group Inc (OTCMKTS:PRED) - The Oracle Dispatch

Posted in Regenerative Medicine | Comments Off on The Bounce is On in Predictive Technology Group Inc (OTCMKTS:PRED) – The Oracle Dispatch

Reviewing vTv Therapeutics Inc. (VTVT)’s and Asterias Biotherapeutics Inc. (:)’s results – MS Wkly

Posted: October 27, 2019 at 7:46 am

vTv Therapeutics Inc. (NASDAQ:VTVT) and Asterias Biotherapeutics Inc. (:) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share, top-line revenue and valuation of vTv Therapeutics Inc. and Asterias Biotherapeutics Inc.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Analyst Ratings

In next table is delivered vTv Therapeutics Inc. and Asterias Biotherapeutics Inc.s ratings and recommendations.

vTv Therapeutics Inc. has a 224.68% upside potential and a consensus target price of $5.

Insider & Institutional Ownership

The shares of both vTv Therapeutics Inc. and Asterias Biotherapeutics Inc. are owned by institutional investors at 7.3% and 13.75% respectively. 69.32% are vTv Therapeutics Inc.s share owned by insiders. Insiders Competitively, owned 40.53% of Asterias Biotherapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Summary

vTv Therapeutics Inc. beats Asterias Biotherapeutics Inc. on 6 of the 9 factors.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The companys drug candidate for the treatment of Alzheimers disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. Its type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. operates as a subsidiary of M&F TTP Holdings Two LLC.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. The company also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly

Posted in North Carolina Stem Cells | Comments Off on Reviewing vTv Therapeutics Inc. (VTVT)’s and Asterias Biotherapeutics Inc. (:)’s results – MS Wkly

Reviewing BioCryst Pharmaceuticals Inc. (BCRX)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Posted: October 27, 2019 at 7:46 am

Both BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are each others competitor in the Biotechnology industry. Thus the compare of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

Demonstrates BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 represents BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)s net margins, return on assets and return on equity.

Volatility and Risk

A 2.02 beta means BioCryst Pharmaceuticals Inc.s volatility is 102.00% more than Standard and Poors 500s volatility. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard and Poors 500.

Liquidity

1.8 and 1.8 are the respective Current Ratio and a Quick Ratio of BioCryst Pharmaceuticals Inc. Its rival Brainstorm Cell Therapeutics Inc.s Current and Quick Ratios are 1 and 1 respectively. BioCryst Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

BioCryst Pharmaceuticals Inc.s average price target is $16, while its potential upside is 580.85%. Meanwhile, Brainstorm Cell Therapeutics Inc.s average price target is $9, while its potential upside is 147.25%. Based on the analysts view we can conclude, BioCryst Pharmaceuticals Inc. is looking more favorable than Brainstorm Cell Therapeutics Inc.

Institutional & Insider Ownership

BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. has shares owned by institutional investors as follows: 98.7% and 11.4%. Insiders owned roughly 0.2% of BioCryst Pharmaceuticals Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year BioCryst Pharmaceuticals Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

Summary

BioCryst Pharmaceuticals Inc. beats on 7 of the 12 factors Brainstorm Cell Therapeutics Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

Posted in North Carolina Stem Cells | Comments Off on Reviewing BioCryst Pharmaceuticals Inc. (BCRX)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Functional Medicine Linked To A Higher Quality Of Life, New Study Finds – mindbodygreen.com

Posted: October 27, 2019 at 7:45 am

At mbg, we're no strangers to the benefits of functional medicine. Nutrition, sleep, exercise, stress levels, relationships, and genetics are all major contributors to chronic disease, and sometimes piling medication upon medication just won't cut it.

While we're not suggesting you skip out on your routine checkups, it's becoming increasingly popularcrucial, evenfor people to start thinking about the ways lifestyle factors can influence and help treat disease.

In fact, there's a new study (the first ofits kind, no less!) to actually show how a functional medicine model can provide unique health benefits for patients. What researchers found was that functional medicine can yield a greater quality of life compared to the standard, primary care model of medicine.

The study, published in the Journal of the American Medical Association Network Open, analyzed two groups of patients for two years: 1,595 patients treated at Cleveland Clinic's Center for Functional Medicine and 5,657 patients treated at a primary care health center. To assess each patient's quality of life, researchers used the PROMIS questionnaire, a validated measure by the NIH. This questionnaire assesses patients' global physical and mental health through factors such as fatigue, physical function, pain, gastrointestinal issues, and emotional well-being.

In as little as six months, they saw around 31% of functional medicine patients improve their PROMIS global physical health scores by 5 points or more, an improvement that has a very noticeable effect on daily life, according to the study. Only 22% of primary care patients were able to raise their scores this high.

There are a variety of reasons why functional medicine could have helped raise these patients' scores. Researchers believe that in addition to the holistic, functional medicine model itself, the types of patients seeking functional medicine and whether or not they believe in this model of care could have contributed to these global physical health improvements. While future research is needed to address these concerns, it's exciting that people are now starting to recognize functional medicine as deserving of these evidence-based experiments.

"This is a first-of-its-kind study to evaluate the impact of functional medicine model of care on patients' health-related quality of life," leader of the study Michelle Beidelschies, Ph.D., agrees. "In the past, evidence to support the model has been primarily anecdotal, published as case reports."

What's even more interesting about this study is that the sample of primary care patients actually had a higher median income than the functional medicine group. It speaks to the significant benefits of the functional medicine model that despite these patients' higher financial status, they still had a lower quality of life than the Cleveland Clinic group.

Perhaps these results can inspire even the most traditional of physicians to include integrative medicine into their practiceor, at the very least, allow them to regard functional medicine as a legitimate health care model.

"Functional medicine practitioners have suggested that their patients are improving with a systems-based approach to chronic disease,"Beidelschies says. "Now, they have evidence that their approach is associated with improved quality of life."

With respect to Beidelschies and this new study, it looks like holistic healing is truly becoming a practical measure for patient care. In this case, soul really is meeting science.

Original post:
Functional Medicine Linked To A Higher Quality Of Life, New Study Finds - mindbodygreen.com

Posted in Integrative Medicine | Comments Off on Functional Medicine Linked To A Higher Quality Of Life, New Study Finds – mindbodygreen.com

Dr. Andrew Weil’s True Food Kitchen Opening in Miami at the Falls Mall in South Miami-Dade – Miami New Times

Posted: October 27, 2019 at 7:45 am

True Food Kitchen has opened its first Miami-area restaurant at the Falls.

The health-driven restaurant has replaced the former T.G.I.Friday's and occupies more than 10,000 square feet with an indoor dining room, a patio, and a bar.

"At True Food Kitchen, we believe that every ingredient matters in everything we serve," True Food Kitchen brand chef Robert McCormick says.

True Food Kitchen was bornin Phoenix, Arizona, in 2008 when cofounder Dr. Andrew Weil didnt want to sacrifice flavor for the sake of healthy eating. The Harvard-trained Weil made a name for himself by embracing alternative medicine techniques. The doctor and author is known for books such as The Natural Mind: An Investigation of Drugs and the Higher Consciousness. The prolific doctor also hosts a podcast and sells skincare products and wild-caught seafood on drweil.com.

The integrative medicine doctor wanted to create a restaurant that served food people could enjoy and not regret eating.Eleven years later, there are 28 locations in 17 states, including New York, Louisiana, Colorado, and California. The Falls outpost marks the seventh True Food Kitchen in Florida, with other locations in Boca Raton, West Palm Beach, Palm Beach Gardens, Tampa, Naples, and Jacksonville.

The entire menuis based on Weil's anti-inflammatory food pyramid, which stresses eating more fruits and vegetables and minimizing the consumption of processed foods. The menu offers dishesfilled with whole grains, lean proteins, healthy fats, and limited carbohydrates. "Anti-inflammatory is a lifestyle," says Christine Ferris, senior marketing brand manager for True Food Kitchen.

Each menu item avoids causing the fatigue, bloating, and loss of energy that certain meals create, Ferris says. Even the higher-calorie items on True Food's menu, such as desserts and alcoholic beverages, should be enjoyed without any guilt, according to Ferris.

The menu also changes with the seasons."We change our menu quarterly because it allows us to showcase seasonal ingredients that are nutrient-dense and at the peak of their freshness and flavor, McCormick says. Most items are vegetarian, although chicken, seafood, and even steak are offered. All dishes can also be made gluten-free and can be customized for a particular diet.

True Food Kitchen has incorporated sea buckthorn an orange-red berry into its fall menu. The plant is used in some of the bar's drinks, from the antioxidant mimosa, infused with the berry, cava, honey, and pomegranate, to a ginger margarita ($12), made with ginger liqueur, organic reposado tequila, and honey.

"From nutrient-dense staples and carefully sourced proteins to little-known superfoods, we use the most responsible, creative, in-season ingredients we can find," McCormick says.

The menu includes permanent dishes too. The ancient grain bowl ($14) reflects each level of the anti-inflammatory pyramid by including miso-glazed sweet potato, house-made cilantro paste, turmeric, grilled portobello mushrooms, avocado, and hemp seed. Edamame dumplings, made with dashi and white truffle oil, are another staple on the menu.

The bar also serves organic, biodynamic, and sustainable wines, along with a wide selection of beers.

Ferris says the restaurant localizes its bright and approachable atmosphere by adding local artwork to embody Miamis culture. You will feel the energy when you walk in."

True Food Kitchen is an exciting addition to the shopping center, says the Falls' manager, Dailen Rodriguez. "The community is very wellness-aware, making the restaurant a great fit for our customers."

True Food Kitchen at the Falls. 8888 SW 136th St., Miami; truefoodkitchen.com.Monday through Saturday10 a.m. to 9 p.m.,Sundaynoon to 7 p.m.

See the original post:
Dr. Andrew Weil's True Food Kitchen Opening in Miami at the Falls Mall in South Miami-Dade - Miami New Times

Posted in Integrative Medicine | Comments Off on Dr. Andrew Weil’s True Food Kitchen Opening in Miami at the Falls Mall in South Miami-Dade – Miami New Times

Do Not Let Festive Indulgence Make Room For Increased Acidity; Try These Home Remedies To Stay Healthy This Diwali – Doctor NDTV

Posted: October 27, 2019 at 7:45 am

Diwali 2019: With a change in your diet because of festive indulgence, you may experience increased acidity. Try these home remedies suggested by nutritionist Nmami Agarwal for some effective results.

Acidity home remedies: Poor gut health can be the primary cause of acidity and gas

Diwali 2019: It is Diwali and sweets, fried food, nuts, seeds and even alcohol might be a part of daily diet for most of you. And believe it or not, the increased acidity can be credited to this change in diet and also poor gut health and digestive system. According to lifestyle coach Luke Coutinho, the first step towards preventing indigestion problems like constipation, bloating, acidity and gas is: improve your gut health. This can be done by increasing intake of probiotics and prebiotics, which provide healthy bacteria to your gut and improve overall gut flora. A healthy gut is directly proportional to a healthy digestive system and inversely proportional to the frequency of gas, acidity and other related problems.

In one of her posts on Instagram, nutritionist Nmami Agarwal says that acid is produced in the body to digest food. It is when this acid gets produced in excess that problems like excessive burping, gas, flatulence etc start popping up. In this article, we are going to talk about ways to combat acidity naturally.

Improper eating pattern, consumption of spicy and oily food, lack of physical activity, stress and even dehydration may be possible for acidity. So, regular exercise, a healthy and nutritious diet and sufficient intake of water are the first few steps towards reducing acidity.

Also read:Try This Jeera And Ajwain Tea To Get Rid Of Bloating, Gas And Acidity Once And For All

1. Chew your food properly: The first step of digestion begins right in the mouth, before food even enters the gut. Not chewing your food properly can reduce the action of enzymes present in the mouth. This in turn can lead to partially digested food and more acidity.

Acidity home remedies: Chew your food properly to prevent excess acid productionPhoto Credit: iStock

2. Have a glass of cold milk: Drinking a glass of cold milk is an excellent way to combat acidity. Milk is alkaline in nature and can neutralise stomach pH, thus reducing acidity.

3. Ajwain or carom seeds: Chewing ajwain seeds is the age-old, time-tested remedy for dealing with gas, acidity, bloating and flatulence. Nmami says that you can boil half tsp of ajwain in one glass of water. Strain it, add some lemon juice and a pinch of salt in it. Anti-acidic properties in ajwain can be effective in reducing acidity.

Also read:Here's How You Can Use Ajwain And Hing To Ease Gassiness And Indigestion

4. Mint chaas or buttermilk: According to Nmami, mint chaas or buttermilk too is an excellent remedy to reduce stomach acid. Not only is buttermilk hydrating in nature, it can also neutralise acid in the stomach. Mint on the other hand, is know to lower acid in the stomach. Whenever acidity is giving you a hard time, you can try having mint buttermilk for some quick and effective results.

Mint chaas or mint buttermilk can effectively reduce acidityPhoto Credit: iStock

5. Do not blindly take antacids: Regular consumption of antacids can lead to acid rebound. This means that you stomach begins to produce more acid than before. "This makes your entire gastrointestinal tract go for a toss," says Nmami. Constipation and diarrhoea are only a few of the many side effects of consuming antacids regularly.

Before you think of popping antacids, try the aforementioned home remedies. They might take a little time but they surely can reduce acidity effectively. Wishing you all a very happy, prosperous, safe and healthy Diwali!

Also read:Acidity: Foods To Eat And Avoid

(Nmami Agarwal is nutritionist at Nmami Life)

(Luke Coutinho, Holistic Lifestyle Coach - Integrative Medicine)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

The rest is here:
Do Not Let Festive Indulgence Make Room For Increased Acidity; Try These Home Remedies To Stay Healthy This Diwali - Doctor NDTV

Posted in Integrative Medicine | Comments Off on Do Not Let Festive Indulgence Make Room For Increased Acidity; Try These Home Remedies To Stay Healthy This Diwali – Doctor NDTV

Is There Evidence Behind the Use of Apple Cider Vinegar for Mental Illness? – Everyday Health

Posted: October 27, 2019 at 7:45 am

Among some natural health proponents, apple cider vinegar has gained a reputation as a cure-all. On the website PreventDisease.com, the alternative health author John Summerly writes, The question is not what apple cider vinegar can do, but what can't it do.

He goes on to cite research suggesting how the common kitchen condiment can help fight diabetes, heart disease, allergies, high cholesterol, cancer, and weight gain. Some evidence suggests that it might reduce the inflammation associated with psoriasis.

RELATED: What Is Schizoaffective Disorder?

Some sources, such as an article titled Schizophrenia & Natural Remedies on the website Jung Circle, list cider vinegar as an ingredient that can be used in a formula to soothe the body when you're coming off psychiatric medications.

Other online articles, such as one on Psycom,highlight evidence suggesting that what happens in the gut may be connected to what happens in the brain.

An investigation published in February 2019 in Science Advances suggests that the gut microbiome (the ecosystem of bacteria and microbes that live in the digestive tract) may be linked to schizophrenia (a chronic and severe neurological brain disorder). Based on stool samples, the researchers observed that people with schizophrenia have less-diverse microbiomes that people without schizophrenia.

RELATED: Mental Illness Signs, Symptoms, Treatment, and More

Some alternative health advocates hold that apple cider vinegar may improve overall gut health, and if the gut-mind connection is true, then this acidic natural fermented liquid has the potential to help ease the symptoms of schizophrenia.

Drew Ramsey, MD, a nutritional psychiatrist who incorporates evidence-based nutrition into his treatments, believes that what we eat can affect mental health. He makes dietary recommendations designed to help individuals with depression, anxiety, and emotional wellness concerns.

What we really look for is how do we help people eat a more nutrient-dense diet with foods and nutrients linked to brain health, says Dr. Ramsey, who is an assistant clinical professor of psychiatry at Columbia University College of Physicians and Surgeons in New York City.

His eating plans includeleafy greens, colorful vegetables, B vitamins, minerals like zinc and magnesium, and fish rich inomega-3 fatty acids. Ramsey bases his dietary guidance on studies such as one published in October 2019 in the journal PLoS One, which demonstrated a drop in depression among young adults who followed a Mediterranean-style diet for three weeks.

When it comes to apple cider vinegar and the brain, however, the proof of a relationship is just not there, according to Ramsey.

RELATED: The Truth About Apple Cider Vinegar and Hepatitis C

Apple cider vinegar really has no role in nutritional psychiatry and mental health disorders and to suggest such is to really be speaking without any evidence, he says. I probably prescribe more food to mental health patients than anyone else in America, and I have never prescribed apple cider vinegar.

Ramsey is concerned that some people think cider vinegar is a magic-bullet solution.

There is an idea behind it that drinking apple cider vinegar is going to enhance microbiome diversity, but there is not science behind it yet, he says. We want to guide people with evidence and not hype on the internet.

Ken Duckworth, MD, the medical director of the National Alliance on Mental Illness (NAMI), also warns against apple cider vinegar as a treatment for schizophrenia.

There is no evidence that it is helpful, he says. No rational person would recommend it.

That said, Dr.Duckworth does not discount the value of some natural remedies that may improve aspects of mental health. He points to research demonstrating a brain benefit from omega-3s,cranberries, and the spice turmeric.

For comprehensive information on evidence-based natural health solutions, Duckworth directs individuals to the National Center for Complementary and Integrative Health, the federal governments lead agency for investigating complementary and alternative medicine.

I remain open to research that would help [establish]that there is an alternative remedy that demonstrates efficacy for schizophrenia, he says. Absence of proof is not proof of absence, but you need meaningful proof before you can make assertions."

When it comes to schizophrenia specifically, Dr. Ramsey highlights research published in the journal Nature Communications finding that long-chain omega-3 polyunsaturated fatty acids (PUFAs) in fatty fish such as salmon reduce the risk of psychotic disorders.

The study showed a significant decrease in the progression to schizophrenia in individuals who received omega-3s, he says.

RELATED: Early Treatment Programs for Schizophrenia Multiply

About 1.1 percent of the population in 2014 or about 2.6 million Americans age 18 and older live with schizophrenia, according to the Treatment Advocacy Center. An estimated 40 percent of individuals with the condition go untreated in any given year.

Common symptoms include delusions and hallucinations; alterations of the senses; an inability to sort and interpret incoming sensations, and an inability therefore to respond appropriately; an altered sense of self; and changes in emotions, movements, and behavior.

The American Psychiatric Associationpublishes guidelines for the treatment of schizophrenia, which features information on antipsychotic medications and therapy. Duckworth notes that these schizophrenia medications include Clozaril (clozapine), which is the only FDA-approved medication for suicide risk reduction in patients with schizophrenia.

Ramsey stresses that treatments need to be multimodal, with a combination of responsible medication management, a supportive care team (involving a peer counselor, a psychiatrist, and a case manager), and employment.

Working is good for mental health, he says. For people with psychotic disorders, it provides self-esteem, structure, and an income.

For people with schizophrenia, getting access to appropriate psychiatric and mental health care and supportive employment is much more important than apple cider vinegar, Ramsey adds.

To find resources and help for schizophrenia treatment, Duckworth recommends contacting the National Alliance on Mental Illness (NAMI).

See the article here:
Is There Evidence Behind the Use of Apple Cider Vinegar for Mental Illness? - Everyday Health

Posted in Integrative Medicine | Comments Off on Is There Evidence Behind the Use of Apple Cider Vinegar for Mental Illness? – Everyday Health

Flu antibody protects against numerous and wide-ranging strains – Washington University School of Medicine in St. Louis

Posted: October 26, 2019 at 2:46 pm

Visit the News Hub

Could lead to universal flu vaccine, better flu therapies

A human antibody that protects mice against a wide range of lethal flu viruses could be the key to a universal vaccine and better treatments for severe flu disease, according to a new study from Washington University School of Medicine in St. Louis, Icahn School of Medicine at Mount Sinai in New York City, and Scripps Research in La Jolla, Calif.

Researchers have found an antibody that protects mice against a wide range of lethal influenza viruses, according to a study from Washington University School of Medicine in St. Louis, Icahn School of Medicine at Mount Sinai in New York City, and Scripps Research in La Jolla, Calif. The antibody could serve as a template to aid in design of a universal vaccine that protects against all strains of the virus, and a drug to treat and protect against severe cases of flu, including pandemics.

The research is published Oct. 25 in Science.

There are many strains of influenza virus that circulate, so every year we have to design and produce a new vaccine to match the most common strains of that year, said co-senior author Ali Ellebedy, PhD, an assistant professor of pathology and immunology at Washington University. Now imagine if we could have one vaccine that protected against all influenza strains, including human, swine and highly lethal avian influenza viruses. This antibody could be the key to the design of a truly universal vaccine.

Ellebedy discovered the antibody an immune protein that recognizes and attaches to a foreign molecule in blood taken from a patient hospitalized with flu at Barnes-Jewish Hospital in St. Louis in the winter of 2017. Ellebedy was working on a study analyzing the immune response to flu infection in humans, in collaboration with the Washington University Emergency Care and Research Core, which was sending him blood samples from consenting flu patients. He quickly noticed that this particular blood sample was unusual: In addition to containing antibodies against hemagglutinin, the major protein on the surface of the virus, it contained other antibodies that were clearly targeting something else.

At the time we were just starting, and I was setting up my lab so we didnt have the tools to look at what else the antibodies could be targeting, said Ellebedy, who is also an assistant professor of medicine and of molecular microbiology, and a scholar at Washington Universitys Bursky Center for Human Immunology & Immunotherapy Programs.

He sent three of the antibodies with unknown targets to co-senior author Florian Krammer, PhD, a microbiology professor at the Icahn School of Medicine at Mount Sinai. An expert on neuraminidase the other protein on the surface of the influenza virus Krammer tested the antibodies against his extensive library of neuraminidase proteins. At least one of the three antibodies blocked neuraminidase activity in all known types of neuraminidase in flu viruses, representing a variety of human and nonhuman strains.

The breadth of the antibodies really came as a surprise to us, Krammer said. Typically, anti-neuraminidase antibodies can be broad within a subtype, like H1N1, but an antibody with potent activity across subtypes was unheard of. At first, we did not believe our results. Especially the ability of the antibodies to cross between influenza A and influenza B viruses is just mind-boggling. It is amazing what the human immune system is capable of if presented with the right antigens.

Neuraminidase is essential to flu virus replication. The protein cuts newly formed viruses free of infected cells so they can move on and infect new cells. Tamiflu, the most widely used drug for severe flu infection, works by inactivating neuraminidase.

To find out whether the antibodies could be used to treat severe cases of flu, Krammer and colleagues tested them in mice given a lethal dose of influenza virus. All three were effective against many strains, and one antibody called 1G01 protected mice against all 12 strains tested, representing all three groups of human flu virus, as well as avian and other nonhuman strains.

All the mice survived, even if they were given the antibody 72 hours after infection, Ellebedy said. They definitely got sick and lost weight, but we still saved them. It was remarkable. It made us think that you might be able to use this antibody in an intensive care scenario when you have someone sick with flu and its too late to use Tamiflu.

Tamiflu should be administered within 48 hours of symptoms. A drug that could be used later would help many people diagnosed after the Tamiflu window has closed. But before the researchers could even think of designing such a drug based on the antibody, they needed to understand how it was interfering with neuraminidase.

They turned to co-senior author Ian Wilson, DPhil, a noted structural biologist at Scripps Research. Wilson and Xueyong Zhu, PhD, a staff scientist in his lab, mapped the structures of the antibodies while they were bound to neuraminidase. They found that the antibodies each had a loop that slid inside the active site of neuraminidase like a stick between gears. The loops prevented neuraminidase from releasing new virus particles from the surface of cells, thereby breaking the cycle of viral production in cells.

We were surprised how these antibodies managed to insert a single loop into the conserved active site without contacting the surrounding hypervariable regions, thereby achieving much greater breadth against the neuraminidase of different influenza viruses than we have seen before, Wilson said.

The structures showed that the antibodies provide such broad protection because they target parts of the active site of the neuraminidase protein that is much the same across distantly related flu strains. Even minor changes to that part of the protein could abolish its ability to do its job, thereby preventing the virus from replicating.

The researchers are working on developing new and improved treatments and vaccines for influenza based on antibody 1G01, which has been patented by Washington University.

Neuraminidase has been ignored as a vaccine candidate for a long time, Ellebedy said. These antibodies tell us that it should not have been overlooked. Now that we know what a broadly protective antibody to neuraminidase looks like, we now have an alternative approach to start designing novel vaccines that induce antibodies like this. And that could be really important if we are going to figure out how to design a truly universal vaccine.

Stadlbauer D, Zhu X, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu W, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy IA, Krammer F. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science. Oct. 25, 2019. DOI: science.aay0678

The study was supported by the National Institute of Allergy and Infectious Diseases, contract number HHSN272201400008C and HHSN272201400006C and grant numbers R01 AI117287, R21 AI139813, and U01 AI141990; and the National Institutes of Health (NIH), grant number R56 AI117675.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more:
Flu antibody protects against numerous and wide-ranging strains - Washington University School of Medicine in St. Louis

Posted in Molecular Medicine | Comments Off on Flu antibody protects against numerous and wide-ranging strains – Washington University School of Medicine in St. Louis

Page 1,313«..1020..1,3121,3131,3141,315..1,3201,330..»